Ipca Laboratories
Ipca Laboratories Limited, headquartered in Mumbai, India, is a prominent player in the pharmaceutical industry, specialising in the manufacture and export of active pharmaceutical ingredients (APIs) and finished dosage forms. Founded in 1949, the company has achieved significant milestones, including a robust presence in over 100 countries and a diverse product portfolio that encompasses a wide range of therapeutic areas such as cardiovascular, anti-infective, and pain management. With a commitment to quality and innovation, Ipca Laboratories stands out for its extensive range of generic formulations and APIs, which are produced in state-of-the-art facilities adhering to international standards. The company has garnered a strong market position, recognised for its consistent growth and contributions to healthcare, making it a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Ipca Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipca Laboratories's score of 24 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ipca Laboratories's reported carbon emissions
In 2025, Ipca Laboratories reported significant carbon emissions, totalling approximately 582,391,000 kg CO2e. This figure includes 169,992,000 kg CO2e from Scope 1 emissions, 124,512,000 kg CO2e from Scope 2 emissions, and 287,887,000 kg CO2e from Scope 3 emissions. The combined total for Scope 1 and Scope 2 emissions was about 4360 kg CO2e per unit of revenue, indicating a focus on emission intensity relative to financial performance. The company has set ambitious climate commitments, aiming for a 20% reduction in carbon emissions from both Scope 1 and Scope 2 by 2030, with 2022 as the baseline year. This target reflects a proactive approach to mitigating climate impact within the pharmaceutical sector. Additionally, Ipca Laboratories is committed to achieving net-zero emissions, demonstrating its dedication to long-term sustainability. Overall, Ipca Laboratories is actively working to reduce its carbon footprint while maintaining transparency in its emissions reporting and climate strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 51,938,620 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 598,518,280 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 6,451,465,560 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ipca Laboratories is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
